[Ginsenoside-Rg1 inhibits cell apoptosis induced by beta amyloid]

Cui-Bai Wei1, Jian-Ping Jia, Ping Liang

  • 1Department of Neurology, Xuanwu Hospital, Capital University of Medical Sciences, Beijing 100053, China.

Zhonghua Yi Xue Za Zhi
|November 28, 2008
PubMed
Abstract

Insights

Ginsenoside-Rg1 protects cells from apoptosis by inhibiting beta-amyloid (Abeta) production and reducing caspase-3 expression, offering a potential treatment for Alzheimer's disease.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cell Biology

Background:

  • Alzheimer's disease is characterized by beta-amyloid (Abeta) induced apoptosis.
  • Ginsenoside-Rg1 is a compound with potential therapeutic properties.

Purpose of the Study:

  • To investigate the protective effects of ginsenoside-Rg1 against Abeta-induced apoptosis.
  • To elucidate the underlying mechanisms of ginsenoside-Rg1's action.

Main Methods:

  • Cell culture (CHO cells) with Abeta treatment and ginsenoside-Rg1 intervention.
  • Assays for cell viability (MTT), apoptosis (Annexin V-FITC/PI, TUNEL), and protein expression (Immunofluorescence, Western Blotting) for Abeta and caspase-3.

Main Results:

  • Ginsenoside-Rg1 dose-dependently increased CHO cell viability.
  • Ginsenoside-Rg1 significantly reduced Abeta-induced apoptosis in mutant cells.
  • Ginsenoside-Rg1 decreased the expression of Abeta42 and active caspase-3.

Conclusions:

  • Ginsenoside-Rg1 demonstrates neuroprotective effects against Abeta-induced apoptosis.
  • The mechanism involves inhibiting Abeta42 production and downregulating active caspase-3 expression.
  • Ginsenoside-Rg1 presents a promising therapeutic strategy for Alzheimer's disease.

Related Concept Videos